why VistaGen Therapeutics Inc. [VTGN] is a Good Choice for Investors After New Price Target of $7.33

Related

Share

VistaGen Therapeutics Inc. [NASDAQ: VTGN] jumped around 0.07 points on Wednesday, while shares priced at $2.11 at the close of the session, up 3.43%. The company report on November 16, 2021 that VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference.

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, announced that Shawn Singh, Chief Executive Officer, will participate in a fireside chat with Jefferies analyst, Andrew Tsai as part of the Jefferies Virtual London Healthcare Conference on Thursday, November 18, 2021. Management will be available during the conference for virtual one-on-one meetings.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


A webcast of VistaGen’s presentation will be accessible through the News/Events page of the Investors section of the Company’s website at www.VistaGen.com and will be available for up to 30 days following the conference.

VistaGen Therapeutics Inc. stock is now 8.76% up from its year-to-date (YTD) trading value. VTGN Stock saw the intraday high of $2.12 and lowest of $1.955 per share. The company’s 52-week high price is 3.55, which means current price is +15.30% above from all time high which was touched on 07/02/21.

Compared to the average trading volume of 1.15M shares, VTGN reached a trading volume of 884498 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about VistaGen Therapeutics Inc. [VTGN]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VTGN shares is $7.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VTGN stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Robert W. Baird have made an estimate for VistaGen Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 20, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on February 18, 2021, representing the official price target for VistaGen Therapeutics Inc. stock.

The Average True Range (ATR) for VistaGen Therapeutics Inc. is set at 0.14, with the Price to Sales ratio for VTGN stock in the period of the last 12 months amounting to 282.16. The Price to Book ratio for the last quarter was 5.02, with the Price to Cash per share for the same quarter was set at 0.47.

How has VTGN stock performed recently?

VistaGen Therapeutics Inc. [VTGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.21. With this latest performance, VTGN shares dropped by -8.26% in over the last four-week period, additionally sinking by -21.27% over the last 6 months – not to mention a rise of 183.79% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTGN stock in for the last two-week period is set at 40.44, with the RSI for the last a single of trading hit 41.24, and the three-weeks RSI is set at 40.44 for VistaGen Therapeutics Inc. [VTGN]. The present Moving Average for the last 50 days of trading for this stock 2.46, while it was recorded at 2.10 for the last single week of trading, and 2.55 for the last 200 days.

VistaGen Therapeutics Inc. [VTGN]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and VistaGen Therapeutics Inc. [VTGN] shares currently have an operating margin of -1636.66. VistaGen Therapeutics Inc.’s Net Margin is presently recorded at -1646.09.

Return on Total Capital for VTGN is now -37.92, given the latest momentum, and Return on Invested Capital for the company is -38.44. Return on Equity for this stock declined to -41.59, with Return on Assets sitting at -31.45. When it comes to the capital structure of this company, VistaGen Therapeutics Inc. [VTGN] has a Total Debt to Total Equity ratio set at 4.04. Additionally, VTGN Total Debt to Total Capital is recorded at 3.89, with Total Debt to Total Assets ending up at 3.43. Long-Term Debt to Equity for the company is recorded at 3.64, with the Long-Term Debt to Total Capital now at 3.50.

Reflecting on the efficiency of the workforce at the company, VistaGen Therapeutics Inc. [VTGN] managed to generate an average of -$854,010 per employee. Receivables Turnover for the company is 53.67 with a Total Asset Turnover recorded at a value of 0.02.VistaGen Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.20 and a Current Ratio set at 12.20.

Earnings analysis for VistaGen Therapeutics Inc. [VTGN]

With the latest financial reports released by the company, VistaGen Therapeutics Inc. posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -150.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VTGN.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for VistaGen Therapeutics Inc. [VTGN]

There are presently around $278 million, or 71.20% of VTGN stock, in the hands of institutional investors. The top three institutional holders of VTGN stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 16,302,596, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; VR ADVISER, LLC, holding 16,047,286 shares of the stock with an approximate value of $33.86 million in VTGN stocks shares; and ORBIMED ADVISORS LLC, currently with $27.24 million in VTGN stock with ownership of nearly -10.773% of the company’s market capitalization.

Positions in VistaGen Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 55 institutional holders increased their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] by around 12,491,675 shares. Additionally, 41 investors decreased positions by around 4,184,934 shares, while 23 investors held positions by with 114,917,338 shares. The mentioned changes placed institutional holdings at 131,593,947 shares, according to the latest SEC report filing. VTGN stock had 20 new institutional investments in for a total of 1,568,709 shares, while 11 institutional investors sold positions of 623,320 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam